For most nutraceutical supplements, the journey from factory to pharmacy shelf is an unseen test of survival. Temperature shifts, transport time and interactions between active compounds quietly erode a product’s strength long before a customer opens the bottle. Vitamin C is the clearest example. Its molecular structure is so sensitive that even mild heat can destabilise it if the finished product does not respect the physicochemical properties. Yet under European food regulations governing the supplements, producers are not required to demonstrate that their ingredients remain active throughout a product’s lifespan.
That gap between what labels promise and what consumers actually receive is what pushed John Kottaris to establish Pharmacros, a company that applies pharmaceutical-grade controls to nutritional supplements.
It all began when Kottaris turned to collagen during recovery from an injury. The more he researched, the clearer it became that food regulations ensured hygiene and basic compliance. But they did not require stating how long the actives stayed viable or whether the formulations delivered the benefits they claimed. The issue wasn’t the ingredient itself. It was the absence of a system that required transparency to verify performance.
Most users report visible improvements within 10 days, a response time that contrasts sharply with the 30 to 40 days typical supplements require before any effect is noticeable.
“I realised if a supplement is meant to help people, it must behave like a scientific formulation that performs consistently from the first dose to the last. Anything short of that breaks consumer trust,” says Kottaris, founder and CEO.
For Swiss-based Pharmacros, that principle defines every decision that follows. It works solely with EUapproved branded raw materials supported by clinical studies. Every batch is retested in-house against its certificate of analysis before formulation begins, because it believes that ingredients cannot be trusted unless they are traceable and scientifically supported.
Stability is treated with the same rigour because it directly affects the consumer experience. Temperature shifts and interactions between active compounds are the primary reasons supplements lose strength. Pharmacros produces its liquid formulations at controlled room temperatures below 21 degrees Celsius. These conditions enable up to 11 combined, sensitive ingredients to remain stable together, allowing the final product to maintain a fully homogenised profile batch to batch.
Ensuring that reliability led to one of the company’s most decisive steps. In 2020, Pharmacros shifted manufacturing to an ANSM-approved pharmaceutical GMP facility in Montélimar, France—a site authorised to produce liquid medicines. This move provided the level of uniformity physicians expect when recommending a product and ensured that it always behaves exactly as formulated, regardless of its travel route or storage duration.
Today, formulations are also validated under stress conditions that mirror real-world logistics conditions. During development, they are subjected to accelerated Suitability Test following ICH guidelines—stored for six months at 40 degrees Celsius and 75 percent humidity—as well as Preservative Efficacy Test following European Pharmacopoeia protocol (Ph. Eur 5.1.3). Throughout these evaluations, potency must stay within specification and there should be no changes in viscosity, density or interactions between actives.
When ingredient stability is preserved, trust is strengthened at the consumer level. That assurance is what distinguishes Pharmacros in the supplements category.
The Hero Category that Defines the Standard
Collagen became the proving ground for Pharmacros because it is one of the few supplement categories where the product’s effectiveness is tested by the user almost immediately.
People either feel improvements in their joints, mobility or skin, or they don’t. That is why the science behind collagen peptides matters so much. Clinical studies on branded peptides such as Fortigel and Peptan consistently show that meaningful results require daily gram-level doses, not the milligram quantities found in many supplements. And those studies assume the full dose is accurately delivered each day. If a formulation cannot provide that amount in a form the body can use, the benefits demonstrated in research will not appear in practice.
Format is hence critical. A true 10-gram serving cannot be delivered through tablets or gummies without asking consumers to take an excessive amount. Powders introduce another limitation. Once they are mixed into hot coffee or acidic juice, shifts in temperature and pH can degrade sensitive vitamins within seconds. In such cases, users may believe they are taking the full formulation when, in fact, several actives are already compromised. A ready-to-use liquid avoids these losses. It protects the matrix of active ingredients, keeps the dose accurate and gives users a consistent product every day.
Pharmacros built its proprietary homogenisation process for collagen lines with that discipline in mind. Each 600 ml bottle carries 24 premeasured servings of 10 grams. Up to eleven active ingredients—including vitamins C and D3—are stabilised through controlled production at temperatures below roughly 21 degrees Celsius to prevent any interactions that could weaken the final product.
“We stick to liquid even though it’s harder on us,” says Kottaris. “It needs more certification, it’s heavier to ship and it complicates production. But it’s worth it, because the efficacy is 90 percent higher than anything you can achieve with pills.”
The ingredients themselves reinforce that promise. Pharmacros works only with two collagen producers whose peptides have clinical evidence: Fortigel from Gelita for its Pro-active® ADVANCED line, and Peptan from Rousselot for its Cynergy MED® ADVANCED line.
When the dose is right, the format is engineered to protect it, and the actives stay stable, results follow. Most users report visible improvements within 10 days, a response time that contrasts sharply with the 30 to 40 days typical supplements require before any effect is noticeable. That speed keeps users consistent and gives clinicians confidence to recommend it.
Where Clinical Evidence Replaces Advertising
Across its markets in Europe, the Middle East and Africa, Pharmacros built its most successful networks both through clinical channels and consumer retail. In South Africa, for example, Pharmacros did not launch through pharmacies or consumer channels. Doctors introduced the formulations into recovery cases and joint health protocols. When mobility increased and pain decreased within days, the products began circulating organically. Word spread through the medical community, patients returned for the same bottle because they felt the difference, and within three years, Pharmacros had built one of its strongest networks—without a single advertising or consumer campaign.
-
I realised if a supplement is meant to help people, it must behave like a scientific formulation that performs consistently from the first dose to the last. Anything short of that breaks consumer trust.
The reliability behind those outcomes is reflected in the company’s record. In 15 years of operations, Pharmacros has not registered a single product claim. And in several Middle Eastern markets, where authorities independently test every imported supplement, the formulations continue to meet all requirements. This gives Pharmacros the confidence that its formulations meet global requirements, not just regional ones.
Taking the Standard into New Formats
Pharmacros has never pursued expansion for the sake of it. A small, specialised team allows it to stay close to every decision that affects quality, right from ingredient selection to stability testing. As new markets emerge, that model does not change. Production is scaled through certified partners, but the formulation standards remain in-house.
It is now preparing a new line of solid formulations, due for launch in mid-2026, including vitamins, minerals, amino acids and broader joint-support products. The move is deliberate as the team waited until it could apply the same pharmaceutical-grade standards it uses for liquids to solid formats as well.
Prototypes have gone through extended testing and will not be introduced until stability, potency and performance match the benchmarks already set by its flagship products.
This shift comes at a moment when the nutraceutical supplement market is being reshaped by forces that make Pharmacros’ discipline not only relevant but necessary. Across Europe, Middle Eastern markets and parts of Asia, regulators are tightening requirements around stability data, activeingredient verification and label accuracy. At the same time, clinicians are moving towards products that demonstrate predictable behaviour under the same conditions found in real-world logistics. Pharmacros’ products sit squarely inside these emerging expectations.
As consistency becomes the new currency in nutraceutical supplements, Pharmacros occupies a premier space shaped by its pharmaceutical-grade controls and batch-to-batch consistency.
